insights_auto
Zakaj je tečaj GILD zrasel 2,49%?
Podrobneje raziščichevron_right
GILD:NASDAQ
Gilead Sciences, Inc
157,37 $
arrow_upward
+2,49%(+3,83) 1D
157,51 $
arrow_upward
+0,09% (+0,14)bedtimePo zaprtju
Zaprto: 15. okt., 16:00:01 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za GILD …
Odpri
156,39 $
Visoka
160,51 $
Nizka
156,02 $
Tržna kapitalizacija
195,13 mrd.
Povprečni promet
5,67 mio.
Promet
8,29 mio.
Dividenda
2,08 %
Četrtletna dividenda
0,82 $
Prvi trgovalni dan brez upravičenja do dividende
15. sep. 2026
52-tedenski najvišji tečaj
160,51 $
52-tedenski najnižji tečaj
114,02 $
Čisti dobiček na delnico
−2,66 $
Beta
0,32
Št. izdanih delnic
1,24 mrd.
Št. zaposlenih
17 tis.
Odpri
156,39 $
Visoka
160,51 $
Nizka
156,02 $
Tržna kapitalizacija
195,13 mrd.
Povprečni promet
5,67 mio.
Promet
8,29 mio.
Dividenda
2,08 %
Četrtletna dividenda
0,82 $
Prvi trgovalni dan brez upravičenja do dividende
15. sep. 2026
52-tedenski najvišji tečaj
160,51 $
52-tedenski najnižji tečaj
114,02 $
Čisti dobiček na delnico
−2,66 $
Beta
0,32
Št. izdanih delnic
1,24 mrd.
Št. zaposlenih
17 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
BioSpace
·
pred 10 minutami
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Investing.com Nigeria
·
pred 26 minutami
Form 144 GILEAD SCIENCES For: 16 October By Investing.com
ad-hoc-news.de
·
pred 1 uro
Vir Biotechnology enters Gilead deal: what it means for Vir Biotechnology stock
Zacks
·
pred 6 urami
Gilead Sciences (GILD) Rises Higher Than Market: Key Facts
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Vizitka: Gilead Sciences, Inc
Generalni direktorDaniel O'Day
Št. zaposlenih17 tis.
Ustanovljeno22. jun. 1987
SedežFoster City, Kalifornija, Združene države Amerike
Sektor-
Spletno mestogilead.com